… The doses of UVA1 used for our patients with acute GVHD were based on our experience
in the treatment of chronic GVHD with medium dose UVA1 (50–60 J/cm 2 /treatment). Optimal …

… The median duration of disease was 22.5 years (range, 3-55 years). Three patients had …
, that doses in the medium or even low range might also be preferable for other skin disorders …

… skin type, NB UVB dosage was increased with 0.1 to 0.2 J/cm 2 . Maximum NB UVB dose was
considered 1.3 J/cm 2 for skin … armamentarium of sclerotic skin diseases. The introduction …

… immune-mediated and autoimmune diseases. Although numerous … The efficacy of IVIg in
certain diseases has been proven in … with IVIg therapy for skin diseases and discusses current …

… medium-dose UVA1 therapy for the different skin diseases. In earlier studies, patients were
often treated with higher doses … skin diseases improved in our study with medium-dose UVA1 …

… symptomatic improvement of the skin lesions of AN, prompted … inflammatory and neoplastic
skin diseases characterized by … obtained, or until partial improvement ([50% reduction of skin …

… dose (LD) (10-30 J/cm 2 ) or moderate/medium dose (MD) (40-70 J/cm 2 ). The high output,
high-dose (… Another classification is based on the administered cumulative dose. HD is then …

… autoimmune disorders, including autoimmune blistering skin diseases (2, 3). Rituximab …
disease relapse. Autoimmune blistering skin diseases are a group of heterogeneous skin …

… or intimal hyperplasia and fibrosis of small and medium-sized blood vessels in the dermis
and … kidney, hepatic disease, hyperphosphatemia and the use of high doses of recombinant …

… -mediated autoimmune diseases, which manifest with bullae and erosions on the skin and
… of blisters and erosions in the mouth, pharynx, and skin. Until the advent of steroid treatment, …